Kadimastem Ltd

Tel Aviv Stock Exchange KDST.TA

Kadimastem Ltd EPS (Diluted) for the year ending December 31, 2023: USD -0.08

Kadimastem Ltd EPS (Diluted) is USD -0.08 for the year ending December 31, 2023, a 58.25% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Kadimastem Ltd EPS (Diluted) for the year ending December 31, 2022 was USD -0.18, a 93.22% change year over year.
Kadimastem Ltd EPS (Diluted) for the year ending December 31, 2021 was USD -2.73, a 25.54% change year over year.
Kadimastem Ltd EPS (Diluted) for the year ending December 31, 2020 was USD -3.66, a 31.69% change year over year.
Kadimastem Ltd EPS (Diluted) for the year ending December 31, 2019 was USD -5.36, a 35.12% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

Tel Aviv Stock Exchange: KDST.TA

Kadimastem Ltd

CEO	Mr. Ronen Twito CPA
IPO Date	June 13, 2013
Location	Israel
Headquarters	Pinchas Sapir 7
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Key trends

Past 5 years